Biocon said that the drug could prove to be a multi-billion dollar opportunity for the company.
“We are almost through with the phase II clinical trials of the new molecule, T1H, and in 18 months we expect to start the phase III trials,” said Biocon managing director Kiran Mazumdar Shaw. “So far, the phase two data look good.”
Biocon also said that it was looking at global trials for the phase III testing of the drug.
The company recently launched BIOMAb-EGFR a therapeutic monoclonal antibody for treating head and neck cancers. The drug is the first of its kind to be clinically developed in India.
Established in 1978, Biocon delivers products and solutions to partners and customers across 50 countries.